Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

Immune cells are being engineered to recognize and respond to disease states, acting as a
“living drug” when transferred into patients. Therapies based on engineered immune cells …

The advent of chimeric antigen receptor (CAR) T cell therapy has resulted in unprecedented
long-term clearance of relapse/refractory hematological malignancies in both pediatric and …

Chimeric antigen receptor (CAR) T cells have achieved true clinical success in treating
hematological malignancy patients, laying the foundation of CAR T cells as a new pillar of …

The growing clinical success of hematopoietic stem/progenitor cell (HSPC) gene therapy
(GT) relies on the development of viral vectors as portable" Trojan horses" for safe and …

Engineered T cells expressing chimeric antigen receptors (CARs) have been proven as
efficacious therapies against selected hematological malignancies. However, the approved …

Advancements in chimeric antigen receptor engineered T-cell (CAR-T) therapy have
revolutionized treatment for several cancer types over the past decade. Despite this success …

Equipping cancer-fighting immune cells with chimeric antigen receptor (CAR) has gained
immense attention for cancer treatment. CAR-engineered T cells (CAR T cells) are the first …

CRISPR technology has transformed multiple fields, including cancer and immunology.
CRISPR‐based gene editing and screening empowers direct genomic manipulation of …

Chimeric antigen receptor T‐cell (CAR‐T) therapy has emerged as a highly efficacious
treatment modality for refractory and relapsed hematopoietic malignancies in recent years …